Home Immunology & Inflammation GPX

GPX

Immunology & Inflammation

LSD1 JMJD DNMT EZH1/2 G9a/GLP PRMT SETD MLL COMT DOT1 HNMT WDR5 SAM MTase PPMTase FTO MAT2A NNMT
  • All (2)
  • GPX Inhibitors (2)
  • New GPX Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8155 RSL3 RSL3 ((1S,3R)-RSL3) is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis.
Rockefeller University Digital Commons @ RU, 221, 670
Exp Cell Res, 2026, 454(1):114825
Nature, 2025, 10.1038/s41586-025-09222-5
Verified customer review of RSL3
E6610New GPX4-IN-5 GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research.
S8155 RSL3 RSL3 ((1S,3R)-RSL3) is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis.
Rockefeller University Digital Commons @ RU, 221, 670
Exp Cell Res, 2026, 454(1):114825
Nature, 2025, 10.1038/s41586-025-09222-5
 Verified customer review of RSL3
E6610New GPX4-IN-5 GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research.
E6610New GPX4-IN-5 GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research.